Evaxion Biotech A/S

AI Score

XX

Unlock

1.61
-0.04 (-2.42%)
At close: Apr 28, 2025, 1:25 PM

Company Description

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections.

The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.

Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases.

The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Evaxion Biotech A/S
Evaxion Biotech A/S logo
Country DK
IPO Date Feb 5, 2021
Industry Biotechnology
Sector Healthcare
Employees 46
CEO Christian Kanstrup M.Sc.

Advertisement

Contact Details

Address:
Dr. Neergaards Vej
Horsholm,
DK
Website https://www.evaxion-biotech.com

Stock Details

Ticker Symbol EVAX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001828253
CUSIP Number 29970R105
ISIN Number US29970R2040
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Christian Kanstrup M.Sc. Chief Executive Officer
Thomas Frederik Schmidt M.Sc. Interim Chief Financial Officer
Andreas Holm Mattsson Founder & Chief AI Officer
Dr. Birgitte Rono Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Apr 10, 2025 6-K Filing
Apr 07, 2025 6-K Filing
Apr 01, 2025 20-F Filing
Apr 01, 2025 6-K Filing
Mar 27, 2025 6-K Filing
Mar 26, 2025 6-K Filing
Mar 26, 2025 424B5 Filing
Mar 25, 2025 6-K Filing
Mar 13, 2025 F-3 Filing
Mar 04, 2025 6-K Filing